The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports


Can We Make a Pill to End the Pandemic?

Contributed Opinion
  ()
Vision and Value discusses the state of the virus and big pharma's race to slow the death rate as well as the spread of the pandemic — and what it means for investors.

Chen's Top Picks for Q2 2022

  ()
Asset manager and contributing writer Chen Lin looks to the biotechnology and mining sectors for his top second quarter picks.

Co. Awaits FDA Approval of Drug, Prepares for Launch

Research Report
  ()
The biopharma's executive team is managing both time and opex spending well, noted an Oppenheimer report.

Drug Co. Gets PDUFA Date for TKI

Research Report
  ()
"We expect poziotinib approval in late 2022 with sales of $21.9 million this year," noted an H.C. Wainwright & Co. report.

Catalyst Could Push Pharma to Break Out

Contributed Opinion
  ()
This pharmaceutical company is trading well below its cash value and is on the cusp of a potentially significant catalyst, one analyst says.

Biotech Firm Should Increase Sales by 20% This Year

Research Report
  ()
This immunotherapy company's outlook for 2022 is positive with expected growth in overall product sales and progress on the clinical front, noted an H.C. Wainwright & Co. report.

Co.'s Catalyst Rich 2022 Includes NDA, MAA Filings

Research Report
  ()
An Oppenheimer report notes that this pharmaceutical company is working to expand the approved uses of its lead drug candidate, and numerous catalysts involving Empaveli are expected this year.

This Year Should Be Catalyst Rich for Oncology Pharma Co.

Research Report
  ()
An outperform-rated biopharma, which has a robust year of significant events ahead, is trading now at a significant discount, noted a Wedbush report.

Biotech to Take Novel Cancer Drug to Market in H1/22

  ()
This biotech company is commercializing its lead drug candidate, Kimmtrak, has a catalyst-rich 2022, and has various clinical-stage drugs for cancers and autoimmune and infectious diseases.

Super Computers Create Powerful Drugs for Alzheimer's

  ()
A promising biotech company is finding new ways to treat neurodegenerative diseases by focusing on misfolded proteins.

Showing Results: 26 to 50 of 108 Prev Next

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts